<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/696ECD9F-168F-46D9-9411-D67B47D04DB0"><gtr:id>696ECD9F-168F-46D9-9411-D67B47D04DB0</gtr:id><gtr:name>Sense about Science</gtr:name><gtr:address><gtr:line1>Sense about Science</gtr:line1><gtr:line2>60 Cambridge Street</gtr:line2><gtr:postCode>SW1V 4QQ</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF11C8EB-DE92-4FC8-8F5D-477390597C44"><gtr:id>CF11C8EB-DE92-4FC8-8F5D-477390597C44</gtr:id><gtr:name>McMaster University</gtr:name><gtr:address><gtr:line1>1280 Main Street West</gtr:line1><gtr:line4>Hamilton, Ontario</gtr:line4><gtr:line5>L8S 4L8</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48A39E65-3FDC-49A8-9E29-B55CEA0CDDC5"><gtr:id>48A39E65-3FDC-49A8-9E29-B55CEA0CDDC5</gtr:id><gtr:name>James Lind Alliance</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B46BA3F6-5108-4148-B5DA-5BE769CFCA05"><gtr:id>B46BA3F6-5108-4148-B5DA-5BE769CFCA05</gtr:id><gtr:name>Food and Drug Administration (FDA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2294A225-2437-4CA3-94DA-50340C98A54E"><gtr:id>2294A225-2437-4CA3-94DA-50340C98A54E</gtr:id><gtr:name>Duke University Medical Centre</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/696ECD9F-168F-46D9-9411-D67B47D04DB0"><gtr:id>696ECD9F-168F-46D9-9411-D67B47D04DB0</gtr:id><gtr:name>Sense about Science</gtr:name><gtr:address><gtr:line1>Sense about Science</gtr:line1><gtr:line2>60 Cambridge Street</gtr:line2><gtr:postCode>SW1V 4QQ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF11C8EB-DE92-4FC8-8F5D-477390597C44"><gtr:id>CF11C8EB-DE92-4FC8-8F5D-477390597C44</gtr:id><gtr:name>McMaster University</gtr:name><gtr:address><gtr:line1>1280 Main Street West</gtr:line1><gtr:line4>Hamilton, Ontario</gtr:line4><gtr:line5>L8S 4L8</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48A39E65-3FDC-49A8-9E29-B55CEA0CDDC5"><gtr:id>48A39E65-3FDC-49A8-9E29-B55CEA0CDDC5</gtr:id><gtr:name>James Lind Alliance</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B46BA3F6-5108-4148-B5DA-5BE769CFCA05"><gtr:id>B46BA3F6-5108-4148-B5DA-5BE769CFCA05</gtr:id><gtr:name>Food and Drug Administration (FDA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2294A225-2437-4CA3-94DA-50340C98A54E"><gtr:id>2294A225-2437-4CA3-94DA-50340C98A54E</gtr:id><gtr:name>Duke University Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8F91D8A6-2743-4F23-9EEC-3D2EF168FBB5"><gtr:id>8F91D8A6-2743-4F23-9EEC-3D2EF168FBB5</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:surname>Bowman</gtr:surname><gtr:orcidId>0000-0003-1125-8616</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F24413F9-E4DD-4766-A001-A6EE57B766E0"><gtr:id>F24413F9-E4DD-4766-A001-A6EE57B766E0</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3843697-EACF-4836-9052-44E6043B606D"><gtr:id>C3843697-EACF-4836-9052-44E6043B606D</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Armitage</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C245FDB4-7964-48C0-AADD-A63A7A87743A"><gtr:id>C245FDB4-7964-48C0-AADD-A63A7A87743A</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/10D9EDDD-90BD-45A5-B620-831BC7AC90EC"><gtr:id>10D9EDDD-90BD-45A5-B620-831BC7AC90EC</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Emberson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A0EF6BCA-9925-46DE-BA83-96D25371ABDF"><gtr:id>A0EF6BCA-9925-46DE-BA83-96D25371ABDF</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Landray</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/318B2157-DBD8-4366-BCF0-90E3FB15A75B"><gtr:id>318B2157-DBD8-4366-BCF0-90E3FB15A75B</gtr:id><gtr:firstName>Zhengming</gtr:firstName><gtr:surname>Chen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5B9375D1-6527-47E9-92B5-976E7F3674F4"><gtr:id>5B9375D1-6527-47E9-92B5-976E7F3674F4</gtr:id><gtr:firstName>Alex</gtr:firstName><gtr:surname>Baxter</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/471C1D6F-9A76-4E0F-90CD-D85FE25D8283"><gtr:id>471C1D6F-9A76-4E0F-90CD-D85FE25D8283</gtr:id><gtr:firstName>T</gtr:firstName><gtr:surname>Sprosen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90232D94-C2A5-4E0C-9214-D1F2E407E8B7"><gtr:id>90232D94-C2A5-4E0C-9214-D1F2E407E8B7</gtr:id><gtr:firstName>Christine</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Reith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F24D4F73-2C89-4052-9485-F6B0A44E71B8"><gtr:id>F24D4F73-2C89-4052-9485-F6B0A44E71B8</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Haynes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/42EA1F7C-61E8-4457-99C1-1437D6FEC7F6"><gtr:id>42EA1F7C-61E8-4457-99C1-1437D6FEC7F6</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Bulbulia</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AA2AE571-69F8-46E6-AF9B-B27E8D0E2B93"><gtr:id>AA2AE571-69F8-46E6-AF9B-B27E8D0E2B93</gtr:id><gtr:firstName>MD</gtr:firstName><gtr:surname>Lay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F4479AD7-66C1-4474-8AB6-E8F33ACCEBC0"><gtr:id>F4479AD7-66C1-4474-8AB6-E8F33ACCEBC0</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Baigent</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/14D41ED2-2C93-4827-964E-CFC179913196"><gtr:id>14D41ED2-2C93-4827-964E-CFC179913196</gtr:id><gtr:firstName>Carol</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Knott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0688D1E8-800A-4CC8-A843-F41340BAA8D7"><gtr:id>0688D1E8-800A-4CC8-A843-F41340BAA8D7</gtr:id><gtr:firstName>Jemma</gtr:firstName><gtr:otherNames>Caroline</gtr:otherNames><gtr:surname>Hopewell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BA3A40E5-534B-402B-AF40-5EC1FDF91ED1"><gtr:id>BA3A40E5-534B-402B-AF40-5EC1FDF91ED1</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Parish</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3A08924-3211-47F9-A709-DC28DAD85A96"><gtr:id>C3A08924-3211-47F9-A709-DC28DAD85A96</gtr:id><gtr:firstName>Rory</gtr:firstName><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137686860"><gtr:id>200919A6-B682-44DE-AEB4-F9EC047B63EB</gtr:id><gtr:title>Innovating in Large-Scale Epidemiology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137686860</gtr:grantReference><gtr:abstractText>Effective healthcare is critically dependent on reliable evidence from high-quality clinical trials and observational studies. Over the last few decades we have pioneered the use of streamlined designs ? for example, large randomised trials involving tens of thousands of participants, and even larger observational studies, such as the UK Biobank and China Kadoorie Biobank, each involving over 0.5 million people. Such studies need to be carefully designed to provide reliable answers and streamlined so that the study can be conducted, analysed and reported within the available time and resources. 
Many of these advances are possible by the close working of our scientists with our IT experts and these developments have transformed how large scale studies are conducted. For example, we pioneered the use of simple to use touch-screen questionnaires in large studies and developed sophisticated tools to review any adverse events of drugs being evaluated in a clinical trial. Our current and future work is also extending the scope and range of linking to routine health records for the long-term follow-up of our research participants. 
The next 5 years will see significant expansion in this work, and we will play a central role in Oxford University?s major initiative to develop a ?Big Data Institute?.</gtr:abstractText><gtr:technicalSummary>Effective healthcare is critically dependent on reliable evidence from high quality clinical trials and observational studies. However, there is widespread concern that rising costs, driven by cumbersome study design and burdensome research regulation has made such studies substantially more difficult and expensive to conduct.
This programme aims to promote and deploy the streamlined design, conduct and analysis of high quality large-scale clinical trials and observational studies; maximize opportunities for effective and efficient epidemiological research provided by large-scale studies; and encourage proportionate, efficient and coordinated research regulation.
Over the last few decades we have pioneered the use of streamlined designs ? for example, large randomised trials involving tens of thousands of participants, and even larger observational studies, such as the UK Biobank and China Kadoorie Biobank, each involving over 0.5 million people.
The next 5 years will see significant expansion in this work, and we will play a central role in Oxford University?s major initiative to develop a ?Big Data Institute?. The emerging field of Big Data offers the potential for seismic changes in the scale (breadth, depth and duration) and efficiency (data accumulation, storage, processing and dissemination) of clinical studies, enhancing our expertise in recruiting, phenotyping and assessing outcomes in very large cohorts.
In order to maximise the scientific and public health returns from these new opportunities, it will be important to design systems and approaches that are focused on the key drivers of study quality and essential to ensure that their appropriate use is unencumbered by disproportionate regulatory or bureaucratic obstacles. In parallel, we will play a leading role in tackling obstacles to high quality research caused by inappropriate regulation.</gtr:technicalSummary><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2689682</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>James Lind Alliance</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MoreTrials Campaign</gtr:description><gtr:id>AF884D9B-AAC6-4951-BDD2-E920B49271D9</gtr:id><gtr:impact>A letter prepared by CTSU has been signed by more than 100 trialists in 22 countries and 5 research organisations and sent to the European Medicines Agency, EMA pointing out the fundamental problems with ICH-GCP, the structural problems with ICH itself and the failure of ICH's recent proposed update to address these problems.</gtr:impact><gtr:outcomeId>56d8145dddd554.89943449-2</gtr:outcomeId><gtr:partnerContribution>Collaborations are helping to promote the campaign and helping to write new guidelines for the conduct of high-quality randomised trials.</gtr:partnerContribution><gtr:piContribution>CTSU set up and leads this new campaign in partnership with the charity, Sense About Science, London. The aim is to remove regulatory and other barriers to the conduct of high-quality randomised trials. Currently, more than 100 trialists from 22 countries along with 5 research organisations have signed up to support the campaign.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sense about Science</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MoreTrials Campaign</gtr:description><gtr:id>0BB3F490-4A6A-40A5-8C9C-E17446BD407E</gtr:id><gtr:impact>A letter prepared by CTSU has been signed by more than 100 trialists in 22 countries and 5 research organisations and sent to the European Medicines Agency, EMA pointing out the fundamental problems with ICH-GCP, the structural problems with ICH itself and the failure of ICH's recent proposed update to address these problems.</gtr:impact><gtr:outcomeId>56d8145dddd554.89943449-1</gtr:outcomeId><gtr:partnerContribution>Collaborations are helping to promote the campaign and helping to write new guidelines for the conduct of high-quality randomised trials.</gtr:partnerContribution><gtr:piContribution>CTSU set up and leads this new campaign in partnership with the charity, Sense About Science, London. The aim is to remove regulatory and other barriers to the conduct of high-quality randomised trials. Currently, more than 100 trialists from 22 countries along with 5 research organisations have signed up to support the campaign.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Sensible Guidelines for the Conduct of Clinical Trials</gtr:description><gtr:id>AC8693B2-6B5D-4788-A737-FEB8208DEE40</gtr:id><gtr:impact>Improve regulatory environment for clinical trials</gtr:impact><gtr:outcomeId>jgtxRysnTy8-1</gtr:outcomeId><gtr:partnerContribution>Academic collaborators</gtr:partnerContribution><gtr:piContribution>Co-ordinated by CTSU with Duke &amp;amp; McMaster Universities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Food and Drug Administration (FDA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Clinical Trials Transformation Initiative CTTI</gtr:description><gtr:id>15AEFED0-86F8-42BB-8576-297CEDE84A5E</gtr:id><gtr:impact>See publications &amp;amp; regulators (FDA and EMA) have issued revised guidance on risk-based monitoring,</gtr:impact><gtr:outcomeId>J9LAxEQr41M-1</gtr:outcomeId><gtr:partnerContribution>Multi-stakeholder group to to identify and promote practices that will increase the
quality and efficiency of clinical trials.</gtr:partnerContribution><gtr:piContribution>Member of steering committee. Co-chair Trial Monitoring Project (2008-12), Co-chair Quality by Design Project (2012-2016); Membership of Antibacterial Drug Development Working Group (2013-2014) Co-chair Mobile Trials Novel Endpoints Project (2016-); Contributions to projects related to efficient trial design, delivery and analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Clinical Trials Transformation Initiative CTTI</gtr:description><gtr:id>B313B167-9F36-49B4-9950-5ADA7FE4B09B</gtr:id><gtr:impact>See publications &amp;amp; regulators (FDA and EMA) have issued revised guidance on risk-based monitoring,</gtr:impact><gtr:outcomeId>J9LAxEQr41M-2</gtr:outcomeId><gtr:partnerContribution>Multi-stakeholder group to to identify and promote practices that will increase the
quality and efficiency of clinical trials.</gtr:partnerContribution><gtr:piContribution>Member of steering committee. Co-chair Trial Monitoring Project (2008-12), Co-chair Quality by Design Project (2012-2016); Membership of Antibacterial Drug Development Working Group (2013-2014) Co-chair Mobile Trials Novel Endpoints Project (2016-); Contributions to projects related to efficient trial design, delivery and analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McMaster University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Sensible Guidelines for the Conduct of Clinical Trials</gtr:description><gtr:id>BDB1D06C-A085-4F80-92E6-1EA705AE5C8C</gtr:id><gtr:impact>Improve regulatory environment for clinical trials</gtr:impact><gtr:outcomeId>jgtxRysnTy8-2</gtr:outcomeId><gtr:partnerContribution>Academic collaborators</gtr:partnerContribution><gtr:piContribution>Co-ordinated by CTSU with Duke &amp;amp; McMaster Universities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Drug Information Association, Chicago, 2011: Session Chair and speaker: Quality by Design: Planning Quality on Multiple Fronts</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5DE10F2-F49D-44EF-BC32-F393F38DE094</gtr:id><gtr:impact>Increased awareness of using quality by design principles in designing randomised trials.

None.</gtr:impact><gtr:outcomeId>54647d8668cb25.76803955</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Induction training for new members of CAG on research databases</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7F533A74-B50F-4E99-8FAA-22E5B15622B7</gtr:id><gtr:impact>Training for new CAG members on research databases to support large-scale cohorts and randomised trials.</gtr:impact><gtr:outcomeId>56d818de328df9.89913228</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Life Sciences Strategy Workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6514D5D4-99EE-4165-B065-731F529BA539</gtr:id><gtr:impact>Office for Life Sciences (Dept of Health/Dept of Business Enterprise, Innovation and Skills) Life Sciences Strategy Workshop</gtr:impact><gtr:outcomeId>58c2b5dfa8f967.88212048</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media coverage: Testing, Testing</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D442218E-4DC9-4BE7-89E3-0570918DD9FC</gtr:id><gtr:impact>To highlight the value of reliable evidence from randomised trials and the current barriers to their conduct.

None.</gtr:impact><gtr:outcomeId>546495148976b0.50183600</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.economist.com/news/britain/21608775-nation-losing-its-grip-valuable-industry-testing-testing</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation in careers fair/key skills workshop for year 10 pupils (South Wolds Academy, Notts)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>687C1925-097B-4245-8574-C9BB97CFC4DD</gtr:id><gtr:impact>More than 100 year-10 pupils attended talk on a career is medical research and workshop on the obesity epidemic to highlight key principles in epidemiology.

Invited back on several occasions to give other talks about a career in science.</gtr:impact><gtr:outcomeId>544aa99c9d6e98.78074510</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Japanese Circulation Society: 2014 - Speaker How can we conduct sensible investigator-initiated clinical research? Purposes, study design, infrastructure and regulation&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3CC201F4-1D65-4309-95A5-9C8A30E898D9</gtr:id><gtr:impact>To increase awareness of more efficient to conduct large randomised trials.

None.</gtr:impact><gtr:outcomeId>546493c9cf0723.57964072</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Isis Innovation &amp; Oxford AHSN Technology Showcase 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D27BF38-E448-4CD9-A92E-2CA643E00482</gtr:id><gtr:impact>eHealth &amp;amp; Big Data - Innovation with Impact</gtr:impact><gtr:outcomeId>56dedddd82cb14.04191944</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Drug Information Association, Chicago, 2011: Session Chair and speaker: Monitoring and source verification: New approaches to quality</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1B3C4724-66C5-4142-961B-621D0E9EA40F</gtr:id><gtr:impact>To highlight new approaches to trial monitoring.

None.</gtr:impact><gtr:outcomeId>54647f2a61a409.63117836</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Hubs for Trials Methodology Research, Liverpool UK, 2012: Speaker - Current perspectives on monitoring in clinical trials:  Clinical Trials Transformation Initiative update and recommendations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>29FA9EEA-35F3-4E4B-963B-804C917C395F</gtr:id><gtr:impact>To increase awareness of using quality by design principles for randomised trial design.

None.</gtr:impact><gtr:outcomeId>546486d7138409.25409996</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Hubs for Trials Methodology Research, Annual Meeting, Birmingham UK, 2012:  Speaker FDA Clinical Trial Transformation Initiative Monitoring Project: Developing effective quality systems in clinical trials</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>76187199-581C-4A61-8FBF-3124AB77173C</gtr:id><gtr:impact>To increase awareness of using quality by design principles in randomised trial design.

None.</gtr:impact><gtr:outcomeId>546483626e54b9.51078948</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Society for Clinical Trials, Miami, 2012 Session: Update on the Clinical Trials Transformation Initiative: Session chair and speaker - Rethinking approaches to clinical trial oversight and premarket safety management</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CBE72685-81E4-4212-A150-7B069560CDDB</gtr:id><gtr:impact>To increase awareness of more effective ways to manage and monitor randomised trials.

None.</gtr:impact><gtr:outcomeId>54647fd18f4423.66081453</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FDA Clinical Trial Transformation Initiative Anti-Bacterial Drug Development Group - Member of Working Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A7ABC27B-D556-4F99-B704-D5624A4C5823</gtr:id><gtr:impact>To increase awareness of efficient ways to conduct randomised trials to improve anti-bacterial drug development.

None.</gtr:impact><gtr:outcomeId>5464930ee8f3e7.86358500</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation in HRA public dialogue  workshop to give expert input on health research</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E34ECCAA-6EA5-451F-B5D8-444018C9F58A</gtr:id><gtr:impact>Public dialogue organised by HRA on issues on use of health records for research, simple consent models and more widespread use of randomised trials.</gtr:impact><gtr:outcomeId>56d82c77db6a44.26528048</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Training on risk/benefits of research to UKCRC Registered CTU QA Away Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0723F98B-6B14-4AF7-9AA6-412487B12E02</gtr:id><gtr:impact>Training session for QA staff on risks and benefits of research</gtr:impact><gtr:outcomeId>56d829010360d6.25258149</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DRUG INFORMATION ASSOCIATION, Webinar, 2013: Chair and speaker - Clinical Trials: Rethinking How We Ensure Quality</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5038EC48-5FA2-4B06-9A77-758A71A70426</gtr:id><gtr:impact>To increase awareness of adopting quality by design principles to design randomised trials.

None.</gtr:impact><gtr:outcomeId>5464817330fdf7.38947241</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Society for Clinical Trials, Boston, 2013: Speaker - Monitoring Trials Efficiently</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>723F4E3D-509B-42F3-AC35-ED287D163FFD</gtr:id><gtr:impact>To increase awareness of using quality by design principles to improve the monitoring of randomised trials.

None.</gtr:impact><gtr:outcomeId>54648e34969467.85393295</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FDA Clinical Trials Transformation Initiative Quality by Design Training Meetings: course organiser</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>28E799F6-3572-4756-BC4D-51CB3171A711</gtr:id><gtr:impact>Workshops addressed the principles and application of high quality clinical trial methodology through lectures, discussion of principles, exemplars and case studies (conducted in small breakout groups). To date there have been 4 courses (each 1.5 days) held in Bethesda, USA, and 1 arranged in association with EMA in London. These have been attended by senior staff from regulators (FDA, EMA, MHRA), pharmaceutical and medical device companies, clinical research organizations, academia, institutional review boards, and by patient advocates

None.</gtr:impact><gtr:outcomeId>546490c0c8ea45.70911303</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON Webinar, 2012: Speaker - Role of risk-based monitoring in cardiovascular outcomes studies</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>23BFCDF1-6331-488E-B45D-64057A660CD5</gtr:id><gtr:impact>To increase awareness of using a risk-based approach to monitoring to cardiovascular trials.

None</gtr:impact><gtr:outcomeId>54648d114e8e27.88437408</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to year 9/10/11 pupils on how to build a career in scientific research (South Wolds Academy, Notts)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D24C70F5-20D5-4AC1-9186-6BD01E4C124F</gtr:id><gtr:impact>Over 300 year 9/10/11 pupils attended 3 talks.

Invited to speak to other year groups at school.</gtr:impact><gtr:outcomeId>544aaa739300f0.11054729</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>East-West Alliance Global Symposium - Big Data for Precision Medicine Hong Kong 2014: Speaker big-data for population health</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1A93DD7C-4CAA-4A14-AC95-A667927BAD8A</gtr:id><gtr:impact>To increase awareness of the potential of big-data to improve population health.

None.</gtr:impact><gtr:outcomeId>54649023dcb762.60522670</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.med.hku.hk/ewa2014/video14.htm</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media coverage: Clinical trials: how to get closer to the right answer with less effort</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C0979B32-3347-4E0F-A6B0-BFD46D665058</gtr:id><gtr:impact>To highlight modern principles for the efficient conduct of randomised trials and the existing barriers to them.

None.</gtr:impact><gtr:outcomeId>5464970940f254.33938914</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CTSU Participant Panel Meetings</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>870912B0-640D-4D11-99BC-C29E9951D47A</gtr:id><gtr:impact>CTSU Participant Panel was established in 2013 to involve trial participants who live locally in the design, running and dissemination of our studies as well as providing a forum to develop new research ideas.

None.</gtr:impact><gtr:outcomeId>544aa70a3bfc40.32439301</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sensible Guidelines for Clinical Trials, Toronto Canada, 2012: Speaker - Ensuring quality: The role of monitoring</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>97F16E51-754A-4E81-8EA8-E12715D43029</gtr:id><gtr:impact>To increase awareness of using central statistical monitoring to efficiently ensure quality and patient safety in randomised trials.

None.</gtr:impact><gtr:outcomeId>54648da8c3a862.52158608</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media coverage: City is at the forefront of disease prevention</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D88661B7-0788-4B39-B47D-E0EAF08D4512</gtr:id><gtr:impact>To increase awareness of public health research in Oxford.

None.</gtr:impact><gtr:outcomeId>5464960ca2a136.18976854</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.oxfordmail.co.uk/news/11365255.print/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DRUG INFORMATION ASSOCIATION, Boston, 2013: Chair and speaker - Approaches to Quality Risk Management: Understanding What Matters</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AB86EDB0-981E-4953-8872-1BB71D429664</gtr:id><gtr:impact>Increase awareness of using quality by design principles for designing randomised trials.

None.</gtr:impact><gtr:outcomeId>546480c3552129.19476202</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Training for Research Ethic Committee members on the risks and benefits of research</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>54B70219-E386-4379-B1EE-24D04B0E201D</gtr:id><gtr:impact>Risk benefit of research training has been undertaken on two occasions at national HRA training, at the annual REC Chair's meeting and to a Manchester REC. The training was also delivered at the EFGCP annual meeting in January 2014.

Increased awareness of the balance of the risks and benefits of research.</gtr:impact><gtr:outcomeId>544aa8183019b4.33730740</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Hubs for Trials Methodology Research, Oxford UK, 2012: Speaker session on statistical monitoring</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>76D80195-5FA7-4D1F-BC96-A37A54E0EBA8</gtr:id><gtr:impact>To increase awareness of the use of central statistical monitoring for the more efficient conduct of randomised trials.

None.</gtr:impact><gtr:outcomeId>546489aa599377.42484990</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Oxford-Stanford Big Data in Biomedicine conferences: Organising committee and speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>90E2840A-656D-49F9-A4AA-B2EE7C21A624</gtr:id><gtr:impact>To highlight the potential of big-data to improve population health.

None.</gtr:impact><gtr:outcomeId>546491fc1c1926.69128301</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://bigdata.stanford.edu/big-data-for-population-health-martin-landray/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The AHSN Alumni Summit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>511AB775-073A-4A2C-AC2F-5E82F67B076E</gtr:id><gtr:impact>The Alumni Summit
8 - 10 July 2015, Oxford
Strengthening our community of life scientists - at home and abroad</gtr:impact><gtr:outcomeId>56dede1730f793.86817405</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh Clinical Trials Course, Edinburgh UK, 2012: Speaker - Monitoring Trials Efficiently</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>536D3A80-F243-46CF-9E6E-CCBED307F9D5</gtr:id><gtr:impact>To increase awareness of methods available to monitor randomised trials more efficiently.

None.</gtr:impact><gtr:outcomeId>54649141c495d6.97790851</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EE99C1E6-530B-42B9-9C67-B31A66504D43</gtr:id><gtr:impact>Talk to year 8 pupils about heart disease</gtr:impact><gtr:outcomeId>58c2b9aae52ce6.94051749</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Excellence Award (Sensible Guidelines)</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>E4936F63-B744-455C-AF46-53D1FB33A57D</gtr:id><gtr:outcomeId>5433ace9556329.55478251</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Hubs for Trial Methodology Research</gtr:department><gtr:description>Research grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3D6794A7-9DE4-4851-A84F-63F46967BB71</gtr:id><gtr:outcomeId>54636ecd83b0c5.70868316</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3663124</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant</gtr:description><gtr:fundingOrg>UK Biobank</gtr:fundingOrg><gtr:id>D00665F2-FF79-4EDB-A107-6C15DA883458</gtr:id><gtr:outcomeId>54636f7e0962e7.21029167</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital grant Oxford University Big Data Institute</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>5FD8FAA4-1275-419B-8CE4-A8B54182F5F0</gtr:id><gtr:outcomeId>545b8dd9b43252.80430731</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>039F360F-EEA5-4298-9887-018263BBC60E</gtr:id><gtr:outcomeId>54636d6bbe8ae7.24022833</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital grant Oxford University Big Data Institute</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>ACC99277-2783-4147-96A2-2A261F8D02FF</gtr:id><gtr:outcomeId>545b8d8e3a8ec0.79803240</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>236636</gtr:amountPounds><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research seed grant</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Li Ka Shing Foundation</gtr:fundingOrg><gtr:id>41ACE45B-99CD-4052-B9E7-8E25798A7038</gtr:id><gtr:outcomeId>5433ad61e43a89.52851089</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Assessment Centre IT systems</gtr:description><gtr:fundingOrg>UK Biobank</gtr:fundingOrg><gtr:id>BB9F270D-2462-494A-92C7-1216BB540169</gtr:id><gtr:outcomeId>58c2b7a6508cf5.94407519</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Hubs for Trial Methodology Research</gtr:department><gtr:description>Research grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3D547DE2-A09F-4111-BCD9-1FDF313B84F9</gtr:id><gtr:outcomeId>54636f15c6aa84.64793342</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biomedical Research Centre: Clinical Informatics and Big Data</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>361ADB25-C7E9-4530-AD1F-E6DB0F38F2E6</gtr:id><gtr:outcomeId>58c2b8fbbd4330.55167136</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Merck Sharp and Dohme Ltd</gtr:department><gtr:description>HPS3/TIMI55-REVEAL trial</gtr:description><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>42FDCA39-5DEC-4CCE-9618-E30B6486C9B5</gtr:id><gtr:outcomeId>58c2b89cf3c3c6.15517616</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23988316</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK infrastructure for large-scale genomics research</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FBEE7BFD-0F7E-4811-9E5A-8A87493EC79F</gtr:id><gtr:outcomeId>54636e2ce96658.96634493</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Arthritis Research UK Review of Biobanking</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E7F56E43-E2FF-4012-BA30-B01025FF43FD</gtr:id><gtr:outcomeId>544a86942155a0.55975038</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Develop residential short-training programme on doing streamlined randomised trials</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F4D8EA7D-6C84-4663-9203-7DD307CBC843</gtr:id><gtr:outcomeId>56e03e36678685.38615232</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Wellcome Trust Clinical Trial Data Access Survey</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>234D1250-0FB8-487E-981B-18A1421D8651</gtr:id><gtr:outcomeId>544a84732e9af3.08444122</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MHRA 5-year strategic review</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B5D09B37-274F-4FA0-A63F-C92A118E47B8</gtr:id><gtr:outcomeId>cjsGAabRtq6</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to CTTI Recommendations on the use if central IRBs</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>72EAAD29-B7FF-4B44-9019-3C97A03E009D</gtr:id><gtr:outcomeId>56d824fcabf0a0.01371461</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Academy of Medical Sciences Working Group on Health Research Governance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FB684CFE-F355-4577-B7F5-6A667271405C</gtr:id><gtr:outcomeId>YKck4fCrkzx</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to FDA consultation: Safety Assessment for IND Safety Reporting - Draft Guidance for Industry</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>FE27C0FB-5B9C-44D7-BEE7-5141A9D7B32A</gtr:id><gtr:impact>To improve the efficiency of safety reporting for trials of INDs</gtr:impact><gtr:outcomeId>56d81cfc570d42.43548018</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Letter to Lead MEP on draft EU Clinical Trial Regulation</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>07D9AE28-0729-4F84-AAE1-E76B3A26EBEE</gtr:id><gtr:outcomeId>544aa36b3e1064.36177831</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FDA Revised Guidance (August 2013): Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>5BFCD36A-A5DA-430F-B2C6-121D872A8C0A</gtr:id><gtr:impact>Revised guidance from FDA on a risk-based approach to monitoring directly arose from Clinical Trials Transformation Initiative (CTTI).</gtr:impact><gtr:outcomeId>544e64d7246c37.97415215</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to HSCIC Feedback on the draft terms of reference for the proposed new Independent Group Advising on the Release of Data (IGARD)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E33303E7-B49A-424D-B649-E2904448C7E3</gtr:id><gtr:outcomeId>56d8220b1e97f5.24838390</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to Wellcome Trust Clinical Trial Data Access Survey</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3F91B09E-859B-49A4-A5A8-23BF1A3F896D</gtr:id><gtr:outcomeId>56d82eb93963a2.50671432</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC/DH/MHRA Joint Project on Risk Stratificatrion</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E3DBB7BD-67CB-40AD-AE84-49919D76023C</gtr:id><gtr:outcomeId>hx8ZWhPxmLX</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Response to AMS on initial draft of HRA policy framework for health and social care research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC9A3295-567C-40F2-847B-8F0D0852B256</gtr:id><gtr:outcomeId>56d823e9264ab5.61682765</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to HSCIC Customer Survey - Requirements for Secure Data Access</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B9624410-AA11-4143-8BB8-6CD9F1E1F509</gtr:id><gtr:outcomeId>56d82e367ee926.18121730</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written briefing for Wellcome Trust to give evidence to Health Select Committee inquiry into use of NHS records for research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ED6092CC-9C41-496F-B4A5-CE1B6DD49748</gtr:id><gtr:outcomeId>56d8282decec32.64973588</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Briefing for BHF input to UK government Caldicott Review of Data Security</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C20656E9-03B3-4035-8A09-76D40E0A1AB8</gtr:id><gtr:outcomeId>56d8200009ec09.65313942</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Letter to Lead MEP from UKCRC Directors on draft EU Clinical Trial Regulation</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>7709CDCA-DCFC-40E8-9CA6-818867E8986E</gtr:id><gtr:outcomeId>544aa465c2e224.68107595</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US Institute of Medicine Discussion Framework for Clinical Trial Data Sharing</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>D9727FFE-4293-48D7-9995-499739006273</gtr:id><gtr:outcomeId>544a8608452590.39308221</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Response to Academy of Medical Sciences to the Health Research Authority (HRA) consultation on the UK Health Policy Framework</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0A88DE3C-E3C6-4BB0-9810-8003B8E76120</gtr:id><gtr:impact>HRA policy framework supports conduct of high-quality across all of the UK - number of suggestions made to improve policy</gtr:impact><gtr:outcomeId>56d81ed9911e65.44497543</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Response to EMA &amp;amp; ICH on ICH's proposed update to ICH-GCP guideline</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>9D7AD3CE-C6CF-46FC-91B8-42AABBEA543A</gtr:id><gtr:outcomeId>56d81f5b278e40.66748230</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>REsponse to UKCRC on EudraCT End of Trial Reporting problems</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>B1A67380-DCA8-44DA-8C2F-027E5E078473</gtr:id><gtr:outcomeId>56d821a397db75.15235750</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Response to &amp;quot;How does society use evidence.........&amp;quot; AMS consultation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>97DD6BD8-A75E-4353-B905-CBDD1BF58A94</gtr:id><gtr:outcomeId>56d8212b0564d5.95494824</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Partner with Sense About Science to start campaign to make it much easier to do randomised trials</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7E265944-8796-4228-B310-7B6F17AE1BD7</gtr:id><gtr:outcomeId>56e03ddad3d026.96371032</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Comments to MRC on brefing for MISG Information Governance group for routine healthcare data</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ADA14FFB-6156-4646-B907-2848FE74188B</gtr:id><gtr:outcomeId>56d8208e46c704.94968053</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CTTI Quality-by-Design Co-lead</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B18A85DD-FBAC-4296-AF81-1A9130C3E6F5</gtr:id><gtr:outcomeId>56dda323821749.88546886</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to UKCRC CTUs Network on draft proposals for good practice principles for sharing IPD from publicly funded clinical trials</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6160FB42-2B5D-49A9-A40B-389DB00A1E99</gtr:id><gtr:outcomeId>56d82724d67896.35481762</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to UKCRC on WHO consultation on publication of clinical trial results</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>0D21EC4B-918B-4D5A-8A66-1063D5D44B6F</gtr:id><gtr:outcomeId>56d82dbd17ae13.40530257</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FDA Guidance Review: endpoints in CVD trials</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>77FED6A1-3A15-45EA-B6BF-F10C62643144</gtr:id><gtr:outcomeId>sGz6eY2226U</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to HRA Consent to Simple Trials Consultation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D35BE893-DE8C-4B8C-A158-221D2B35EE51</gtr:id><gtr:outcomeId>56d82bba16c665.74812373</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to HRA information governance review led by Dr mark Taylor, Chair CAG</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>40B87064-8B50-47A0-ADAA-E220817788A3</gtr:id><gtr:outcomeId>56d822b369ccc8.25255820</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response to AMS on DH consultation: protecting personal health and care data</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>140EBD69-D4EC-4268-B63E-6746DD8DAF60</gtr:id><gtr:outcomeId>56d82f0e8dc8f3.08932541</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Meeting with funders MRC, Wellcome Trust, CRUK, AMS to discuss problems with draft EU Clinical Trial Regulation</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>CCBC1911-705F-4709-B1D1-B7EF3377A197</gtr:id><gtr:outcomeId>544aa51d9bf856.94875760</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Department of Health consultation: protecting personal health and care data</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F268FB53-80EC-4845-9BD0-57E631E6B55A</gtr:id><gtr:outcomeId>544a84f8e770c6.75739514</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written comments on HSCIC draft 5-year strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F1FCE519-F84B-4907-8F7C-9CE6F16334C0</gtr:id><gtr:outcomeId>56d825eb238a46.01143342</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ESC Advisor for new EU Clinical Trial Regulation</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>A73F5E18-9DD7-4EC4-9DBB-2B4972BFA932</gtr:id><gtr:impact>significant chapters in ICH guideline development</gtr:impact><gtr:outcomeId>56dda3c200dd28.62879078</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NIHR Carbon Reduction Guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>36F3F600-5CD8-4996-9834-8A9EFE50F34B</gtr:id><gtr:outcomeId>tmY4eAPnzkQ</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Working with local collaborators in Beijing to improve clinical trial regulation in China</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>51E555AF-28E1-4052-842A-FCF57169CECD</gtr:id><gtr:outcomeId>56e03d7db92da7.95915133</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Written response ONS Approved Researcher Consultation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AD81F461-780B-41ED-B4BA-663139767EAB</gtr:id><gtr:outcomeId>56d8268e8eda87.09287257</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ESC Taskforce: Improving patient safety by improving clinical trials</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>61BEA7B0-CA08-4CD1-90EE-8738EA86C05E</gtr:id><gtr:outcomeId>56dda41c47f8b9.57691851</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MHRA Good Clinical Practice Handbook 2012</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F390CDFD-9828-47CC-B34F-2AA2CB91F010</gtr:id><gtr:outcomeId>nQ4MYdGDdcc</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EMA Policy workshops</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>FF20F107-3DAD-459E-9C44-63C623D60623</gtr:id><gtr:outcomeId>gWFyPhDFuJx</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Letter to MHRA on draft EU Clinical Trial Regulation</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>40E81F03-5B5C-4ECB-9D2F-06EB11BFADD8</gtr:id><gtr:outcomeId>544aa3ccafe0b6.31939613</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participation in UKCRC WG and report Efficient Trial Conduct report</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>82E548B5-26C4-40D5-8359-C82865ACD2F0</gtr:id><gtr:outcomeId>56d82d39149fc8.35668548</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FDA/NKF Guideline review: earlier endpoints for chronic kidney disease trials</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>A34248C0-82B2-4D7F-93FB-64AF149AE6EE</gtr:id><gtr:outcomeId>mBSBop6UqE8</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Nuffield Council for Biothics - Big Data</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5A658823-BDEA-441F-862A-AE8FB1B7F7CF</gtr:id><gtr:outcomeId>diQQwcMCEyN</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C1D44949-E1AC-4751-9316-E05C12B2906B</gtr:id><gtr:title>Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e509f9a0ce4a54e729765e42968fdc4b"><gtr:id>e509f9a0ce4a54e729765e42968fdc4b</gtr:id><gtr:otherNames>Aung T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58c66b2be16f52.43425735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B21CBE2A-C61E-4C15-8BEA-06952E54DD88</gtr:id><gtr:title>Clinical Trials: Rethinking How We Ensure Quality</gtr:title><gtr:parentPublicationTitle>Drug Information Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/988e6a451abb2912d45bbac98aaacdef"><gtr:id>988e6a451abb2912d45bbac98aaacdef</gtr:id><gtr:otherNames>Landray M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>VcHYJiNYvuy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2349F95E-D09B-4B10-93CB-53AECC405061</gtr:id><gtr:title>The impact of privacy and confidentiality laws on the conduct of clinical trials.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e076c6ecf685f11a5d56959e53d3dce0"><gtr:id>e076c6ecf685f11a5d56959e53d3dce0</gtr:id><gtr:otherNames>Armitage J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>542975ded103a7.33385967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8F9A266-6753-4D97-BC05-B3C7C07F9F10</gtr:id><gtr:title>Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78bf4acd842867687b701ca1c29e8cd9"><gtr:id>78bf4acd842867687b701ca1c29e8cd9</gtr:id><gtr:otherNames>Staplin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>58bd596ea31692.08374787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE61CF28-A50D-43FE-99D5-54E7877B2A76</gtr:id><gtr:title>FP329IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE</gtr:title><gtr:parentPublicationTitle>Nephrology Dialysis Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262d13d32625db31cd4441acd223ed"><gtr:id>78262d13d32625db31cd4441acd223ed</gtr:id><gtr:otherNames>Morton R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>56d99e86667548.60903941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E08DC9E7-FA56-4B01-8318-1A3F9F1433EC</gtr:id><gtr:title>Improving public health by improving clinical trial guidelines and their application.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0580ad7d95d71801683291bd0ac115fc"><gtr:id>0580ad7d95d71801683291bd0ac115fc</gtr:id><gtr:otherNames>Landray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>58c26b8ca75724.97125703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6430DA48-5910-4DEE-B32B-C68EFDD9698C</gtr:id><gtr:title>Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>58bd59c1bb7e66.22630505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>126C0111-914C-49E1-B34A-6FD484B09A10</gtr:id><gtr:title>Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83fe15402bcf33568a0666dd3843101c"><gtr:id>83fe15402bcf33568a0666dd3843101c</gtr:id><gtr:otherNames>Knirsch C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58c66a67843663.03965049</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>416D2D13-02BD-49F1-AE47-B0E433D4496E</gtr:id><gtr:title>Enhancing clinical evidence by proactively building quality into clinical trials.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/639d499fa06b36c2999c063c9f31215f"><gtr:id>639d499fa06b36c2999c063c9f31215f</gtr:id><gtr:otherNames>Meeker-O'Connell A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>58bd596e654a95.05058670</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EF97D0D-93C0-4DFC-859A-11926704C6AF</gtr:id><gtr:title>Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.</gtr:title><gtr:parentPublicationTitle>American heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9218dd9c4716dbf4af2c43fea22c5174"><gtr:id>9218dd9c4716dbf4af2c43fea22c5174</gtr:id><gtr:otherNames>REVEAL Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-8703</gtr:issn><gtr:outcomeId>58c2b04f06a4a4.30821539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFBF5CE1-DFEC-46BC-9C0C-2B2EA68B9B6E</gtr:id><gtr:title>Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol.</gtr:title><gtr:parentPublicationTitle>Systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c4b82828159552a056e203a4fa1ab49"><gtr:id>2c4b82828159552a056e203a4fa1ab49</gtr:id><gtr:otherNames>Llewellyn-Bennett R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-4053</gtr:issn><gtr:outcomeId>58c66b2c16c947.79665636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76CF7A40-8D07-4679-8B45-4E50DBB8F709</gtr:id><gtr:title>Improving public health by improving clinical trial guidelines and their application.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0580ad7d95d71801683291bd0ac115fc"><gtr:id>0580ad7d95d71801683291bd0ac115fc</gtr:id><gtr:otherNames>Landray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>5aa7c07ab51743.42887699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D791D4EF-1321-4BC0-9EF2-1D2567DD231B</gtr:id><gtr:title>A platform for the remote conduct of gene-environment interaction studies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b7e073da787d74108d4ba169adf625"><gtr:id>52b7e073da787d74108d4ba169adf625</gtr:id><gtr:otherNames>Gallacher J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>541c43be103b58.20096908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2E27CE8-2F2F-4306-B396-38D588E30834</gtr:id><gtr:title>Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78bf4acd842867687b701ca1c29e8cd9"><gtr:id>78bf4acd842867687b701ca1c29e8cd9</gtr:id><gtr:otherNames>Staplin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>58bd596ec47d60.07384107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF86D0E5-6F45-4CAA-9E4F-A90C2AB1170E</gtr:id><gtr:title>Use of electronic health records to ascertain, validate and phenotype acute myocardial infarction: A systematic review and recommendations.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85b253681ee31b5a777f00ca4329a557"><gtr:id>85b253681ee31b5a777f00ca4329a557</gtr:id><gtr:otherNames>Rubbo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn><gtr:outcomeId>58c66f3442ef78.90908761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09097B17-F088-4F4A-86CE-AA59FC7B0D49</gtr:id><gtr:title>Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3e724d1b10b1d17bd75fa918017439a"><gtr:id>a3e724d1b10b1d17bd75fa918017439a</gtr:id><gtr:otherNames>Jackson N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>56d99dc91bd802.74025477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCA52FE4-0BC2-4778-81B9-4AED01606827</gtr:id><gtr:title>Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df74d66b919618634773d74760eabc5"><gtr:id>2df74d66b919618634773d74760eabc5</gtr:id><gtr:otherNames>Mihaylova B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>56d99e4133b003.80160750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D09DB91-8947-46BB-8D78-38C5546B4689</gtr:id><gtr:title>Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/069ebc9d925c17aa28c7fece06fe846f"><gtr:id>069ebc9d925c17aa28c7fece06fe846f</gtr:id><gtr:otherNames>Donnelly H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58c66a670e7b03.84657088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C040489B-55E9-4E56-ADCA-EBE03DBBA2D4</gtr:id><gtr:title>Accuracy of Electronic Health Record Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK Biobank Stroke Outcomes Group.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc177bc67084e61937ac7f2b418f0334"><gtr:id>bc177bc67084e61937ac7f2b418f0334</gtr:id><gtr:otherNames>Woodfield R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c66f33737863.64670636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2703898A-D868-4A22-8BEF-39203B24BBF7</gtr:id><gtr:title>Algorithms for the Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19f7a4e1c59c34d163f8e7dd69ab5dee"><gtr:id>19f7a4e1c59c34d163f8e7dd69ab5dee</gtr:id><gtr:otherNames>Eastwood SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c66f333bed39.55611004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37BF643E-2A3C-4DAB-83E9-99A0CF58BD78</gtr:id><gtr:title>Investigating strategies to improve attendance at screening visits in a randomized trial</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d6d9336d7d5bb8fef7cda202d6fb6c3"><gtr:id>0d6d9336d7d5bb8fef7cda202d6fb6c3</gtr:id><gtr:otherNames>Chen F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>541ab548112f11.45879648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D5F55FF-DBFC-4537-AC36-B358FC8B226C</gtr:id><gtr:title>Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/693c2e12419b4f4ef2d0f9cf56bb344f"><gtr:id>693c2e12419b4f4ef2d0f9cf56bb344f</gtr:id><gtr:otherNames>Morton RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>56d99dc9432e60.00875093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1413D14-2515-4697-96E3-B07D5777BF3D</gtr:id><gtr:title>Sensible guidelines for the conduct of large randomized trials.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8c86118b786122dfe2e6a140fef4b2d"><gtr:id>e8c86118b786122dfe2e6a140fef4b2d</gtr:id><gtr:otherNames>Yusuf S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>541aad74ce7f56.47733098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9B8FD12-0F00-4732-B8CF-3DDC29DA1C6A</gtr:id><gtr:title>Recruiting patients cost-effectively by mail</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e509f9a0ce4a54e729765e42968fdc4b"><gtr:id>e509f9a0ce4a54e729765e42968fdc4b</gtr:id><gtr:otherNames>Aung T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>541ab547d2c0b3.72462417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65DAD0D7-CC99-436D-8143-266939E025AA</gtr:id><gtr:title>Randomised controlled trials: important but overrated?</gtr:title><gtr:parentPublicationTitle>The journal of the Royal College of Physicians of Edinburgh</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/646ef92d4f0cea07a4ed60c63a94152c"><gtr:id>646ef92d4f0cea07a4ed60c63a94152c</gtr:id><gtr:otherNames>Boylan JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1478-2715</gtr:issn><gtr:outcomeId>541ab547493384.67561725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63524D5E-38AE-44C3-82E9-B348DAC17EE0</gtr:id><gtr:title>Counterpoint: &amp;quot;streamlined&amp;quot; does not mean simple.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dc4a9ecc43f4532e806a4d1b58a9c81"><gtr:id>3dc4a9ecc43f4532e806a4d1b58a9c81</gtr:id><gtr:otherNames>Manolio TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>541c43be40d0e2.46674316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3383F27B-4C47-422E-A796-332B47ECF8DE</gtr:id><gtr:title>Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98552430a8c6a655baffc9011159e861"><gtr:id>98552430a8c6a655baffc9011159e861</gtr:id><gtr:otherNames>Zhou SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c66f34722e14.01433732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C940CBE-B25C-4887-9765-0EB62298C75A</gtr:id><gtr:title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56022eb4712f9703d94edab35e2b236b"><gtr:id>56022eb4712f9703d94edab35e2b236b</gtr:id><gtr:otherNames>Sudlow C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56d99dc8be2978.22100655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C801EA99-B659-470A-9AE9-B3A4BB3624EF</gtr:id><gtr:title>Sensible approaches for reducing clinical trial costs.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d8214bc8907efc0a09a1453e392994"><gtr:id>31d8214bc8907efc0a09a1453e392994</gtr:id><gtr:otherNames>Eisenstein EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>ia4sxSb5r5J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6DF3D30-DBAB-492B-83FD-06FBC53550E5</gtr:id><gtr:title>A new pathway for the regulation and governance of health research</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d8a9c7212b5ee2ec7f774e139cb4f68"><gtr:id>1d8a9c7212b5ee2ec7f774e139cb4f68</gtr:id><gtr:otherNames>Academy of Medical Sciences</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>978-1-903401-31-6</gtr:isbn><gtr:outcomeId>XMfYsHqVtK9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A965750-F97C-44FF-B2B4-DDD48361A247</gtr:id><gtr:title>Ensuring trial validity by data quality assurance and diversification of monitoring methods.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>541aad750d2fd6.40459085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C72B802F-4EA9-4247-81B3-8EF76E754070</gtr:id><gtr:title>Sensible guidelines for clinical trials: are current European regulations 'a gift to America'? Interview by Barry Shurlock.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5079851905ee4c5f671c1e3e5a037c87"><gtr:id>5079851905ee4c5f671c1e3e5a037c87</gtr:id><gtr:otherNames>Collins R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>541c43bd7f4185.92950017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56CF6018-AFEB-4BC5-A95A-A8D41DAD5534</gtr:id><gtr:title>Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4660e6a1d6c7ec927ecc2f6e64bb30"><gtr:id>7c4660e6a1d6c7ec927ecc2f6e64bb30</gtr:id><gtr:otherNames>Mafham MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>58bd59c214aa98.87870969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>356D0081-7F14-4402-BE26-4FE94D734F05</gtr:id><gtr:title>How the NHS research governance procedures could be modified to greatly strengthen clinical research</gtr:title><gtr:parentPublicationTitle>Clinical Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32210b6eab29b7812cf339823efba2fd"><gtr:id>32210b6eab29b7812cf339823efba2fd</gtr:id><gtr:otherNames>Haynes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>541ab54475b177.87735961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB7F222-B6D1-4693-A779-9A6A7977958E</gtr:id><gtr:title>Randomized clinical trials--removing unnecessary obstacles.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8150647508a1e4ee538bcba81440d914"><gtr:id>8150647508a1e4ee538bcba81440d914</gtr:id><gtr:otherNames>Reith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>541af6f04402e1.05731814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19DA76B1-73DE-439D-AFD8-F70BC8DEC271</gtr:id><gtr:title>Accuracy of routinely-collected healthcare data for identifying motor neurone disease cases: A systematic review.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f12b2bd209f0aa29b0e193e3ab48b9a9"><gtr:id>f12b2bd209f0aa29b0e193e3ab48b9a9</gtr:id><gtr:otherNames>Horrocks S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c66f349f3328.73113630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3A00A52-0503-4E7D-ACC8-EED8C72A7065</gtr:id><gtr:title>Randomized clinical trials--removing obstacles.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8150647508a1e4ee538bcba81440d914"><gtr:id>8150647508a1e4ee538bcba81440d914</gtr:id><gtr:otherNames>Reith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>541af6f0137465.20174544</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137686860</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>